SAN DIEGO, Oct. 12, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the U.S., today announced that a recent clinical study conducted by renowned Mexico neurologist, Dr. Carlos G. Aguirre-Velazquez, successfully utilized its flagship product Real Scientific Hemp Oil-X™ (RSHO-X™).
The study targeted the reduction in frequency, intensity and duration of convulsive crises in people with tuberous sclerosis complex (TSC) and saw promising results from cannabidiol (CBD) as a treatment for patients with TSC. Other factors observed in the study were quality of life, dependence on heavy prescription drugs and long-term sustainability of treatment with CBD.
The trial was comprised of patients with varying forms of epilepsy, with the majority having TSC, a genetic disorder characterized by the growth of noncancerous (benign tumors) in many parts of the body, including the brain, which can lead to convulsive crises. TSC affects 1 million people worldwide, 50,000 in the U.S. and 20,000 in Mexico.
Results from the trial showed that 60% of participants who used CBD products saw a clinically significant (80-100%) reduction in the frequency of their seizures. Additionally, quality of life metrics such as mood, appetite and cognition saw substantial increases among the patients using CBD. Finally, no serious side effects were reported, only mild ones such as drowsiness and increase in appetite, which eventually disappeared with the need to reduce the dose.
The study concludes that, “The experience of parents and patients with medicinal cannabis (CBD), as reported in our survey, suggests that CBD reduced the frequency, intensity, and duration of convulsive crises secondary to TSC.”
“Each time new study results are published showing the positive effects of CBD on a new indication is a victory for showcasing the therapeutic benefits of CBD and people around the world suffering from a multitude of debilitating conditions,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “We congratulate Dr. Aguirre for his work in unveiling, like he did in this study, that not only is CBD effective in relieving seizures, but also exhibiting that CBD can be used over long periods of time without harm, compared to antiepileptic or broad-spectrum steroids that can have dangerous side effects if used for several years, including vision and damage to major organs.”
HempMeds® Mexico’s product RSHO-X™ was the first-ever cannabis product to receive approval from the federal government of Mexico, COFEPRIS, for importation into the country. Dr. Aguirre will present his findings to an online audience on Thursday, October 12, 2017 on a live event on the Por Grace Facebook at 11:00am CDT (9:00am PDT). For more information and to view the full results of Dr. Aguirre’s study, click here.
About HempMeds® Mexico
HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
[email protected]
www.cmwmedia.com
View original content with multimedia:http://www.prnewswire.com/news-releases/medical-marijuana-inc-subsidiary-hempmeds-mexico-announces-results-from-clinical-study-including-real-scientific-hemp-oil-x-rsho-x-on-patients-with-tuberous-sclerosis-complex-tsc-300535141.html
SOURCE Medical Marijuana, Inc.
